# Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)

> **NCT04361461** · PHASE3 · WITHDRAWN · sponsor: **Apsen Farmaceutica S.A.**

## Conditions studied

- Coronavirus Infections
- SARS-CoV 2
- SARS (Severe Acute Respiratory Syndrome)
- Pulmonary Disease

## Interventions

- **DRUG:** Hydroxychloroquine Sulfate
- **DRUG:** Hydroxychloroquine Sulfate + Azythromycin

## Key facts

- **NCT ID:** NCT04361461
- **Lead sponsor:** Apsen Farmaceutica S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-04-30
- **Primary completion:** 2020-11-04
- **Final completion:** 2020-11-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was canceled before enrollment due to a decision by the Sponsor
- **Last updated:** 2020-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361461, "Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04361461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*